- Home
- VERA vs JANX Comparison
VERA vs JANX Comparison
Compare VERA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERA
- JANX
- Stock Information
- Founded
- VERA 2016
- JANX 2017
- Country
- VERA United States
- JANX United States
- Employees
- VERA N/A
- JANX N/A
- Industry
- VERA Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- VERA Health Care
- JANX Health Care
- Exchange
- VERA Nasdaq
- JANX Nasdaq
- Market Cap
- VERA 1.4B
- JANX 1.4B
- IPO Year
- VERA 2021
- JANX 2021
- Fundamental
- Price
- VERA $21.27
- JANX $24.97
- Analyst Decision
- VERA Buy
- JANX Strong Buy
- Analyst Count
- VERA 8
- JANX 8
- Target Price
- VERA $64.29
- JANX $90.63
- AVG Volume (30 Days)
- VERA 1.2M
- JANX 892.8K
- Earning Date
- VERA 08-05-2025
- JANX 08-07-2025
- Dividend Yield
- VERA N/A
- JANX N/A
- EPS Growth
- VERA N/A
- JANX N/A
- EPS
- VERA N/A
- JANX N/A
- Revenue
- VERA N/A
- JANX $439,000.00
- Revenue This Year
- VERA N/A
- JANX N/A
- Revenue Next Year
- VERA N/A
- JANX $1,470.83
- P/E Ratio
- VERA N/A
- JANX N/A
- Revenue Growth
- VERA N/A
- JANX N/A
- 52 Week Low
- VERA $18.53
- JANX $21.97
- 52 Week High
- VERA $51.61
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- VERA 48.60
- JANX 52.30
- Support Level
- VERA $19.07
- JANX $21.97
- Resistance Level
- VERA $22.74
- JANX $25.93
- Average True Range (ATR)
- VERA 0.97
- JANX 1.61
- MACD
- VERA 0.13
- JANX 0.02
- Stochastic Oscillator
- VERA 59.99
- JANX 60.84
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.